Contact
searchSearch
HMP Global
Login

Multiple Myeloma

Multiple Myeloma
Specialty Channel
News
FDA Grants Accelerated Approval to Iberdomide Combination for Relapsed or Refractory Multiple Myeloma
08/13/2026
Stephanie Holland
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated...
08/13/2026
Oncology
News
Phase 3 MonumenTAL-6 Trial Demonstrates Significant Survival Benefit With Dual-Bispecific Immunotherapy in Relapsed or Refractory Multiple Myeloma
07/23/2026
Stephanie Holland
Results from the phase 3 MonumenTAL-6 trial demonstrated that teclistamab plus talquetamab significantly improved progression-free and overall survival compared with standard therapy in patients with relapsed or refractory multiple myeloma,...
Results from the phase 3 MonumenTAL-6 trial demonstrated that teclistamab plus talquetamab significantly improved progression-free and overall survival compared with standard therapy in patients with relapsed or refractory multiple myeloma,...
Results from the phase 3...
07/23/2026
Oncology
News
Indefinite Lenalidomide Maintenance Fails to Improve Overall Survival in Standard-Risk Multiple Myeloma
07/16/2026
Stephanie Holland
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3...
07/16/2026
Oncology
Peter Voorhees, MD
Videos
MonumenTAL-3 Demonstrates Superior Outcomes With Talquetamab-Based Combinations in Relapsed Multiple Myeloma
07/15/2026
Peter Voorhees, MD
Peter Voorhees, MD, discusses results from the phase 3 MonumenTAL-3 trial showing that talquetamab-based combinations significantly improved progression-free survival and depth of response in relapsed multiple myeloma while maintaining...
Peter Voorhees, MD, discusses results from the phase 3 MonumenTAL-3 trial showing that talquetamab-based combinations significantly improved progression-free survival and depth of response in relapsed multiple myeloma while maintaining...
Peter Voorhees, MD, discusses...
07/15/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Mezigdomide Combination in Relapsed or Refractory Multiple Myeloma
07/13/2026
Stephanie Holland
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug...
07/13/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Significantly Improves Outcomes in Heavily Pretreated Relapsed or Refractory Multiple Myeloma
06/16/2026
Emily Estrada
Results from the SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma.
Results from the SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma.
Results from the SUCCESSOR-2...
06/16/2026
Oncology
News
Talquetamab-Based Regimens Improve Survival in Relapsed or Refractory Multiple Myeloma
06/16/2026
Stephanie Holland
Results from the phase 3 MonumenTAL-3 trial demonstrated that talquetamab-based regimens significantly improved outcomes compared with daratumumab plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma.
Results from the phase 3 MonumenTAL-3 trial demonstrated that talquetamab-based regimens significantly improved outcomes compared with daratumumab plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma.
Results from the phase 3...
06/16/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone in Heavily Pretreated Patients With R/R Multiple Myeloma
05/29/2026
Stephanie Holland
Results from the phase 3 SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in previously treated R/R multiple myeloma.
Results from the phase 3 SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in previously treated R/R multiple myeloma.
Results from the phase 3...
05/29/2026
Oncology
News
Maintenance Carfilzomib Plus Lenalidomide and Dexamethasone Following Autologous HSCT for Newly Diagnosed Multiple Myeloma
04/10/2026
Stephanie Holland
Results from the phase 3 ATLAS trial demonstrate that carfilzomib plus lenalidomide and dexamethasone significantly improves PFS in newly diagnosed patients with multiple myeloma following autologous hematopoietic stem-cell transplantation.
Results from the phase 3 ATLAS trial demonstrate that carfilzomib plus lenalidomide and dexamethasone significantly improves PFS in newly diagnosed patients with multiple myeloma following autologous hematopoietic stem-cell transplantation.
Results from the phase 3 ATLAS...
04/10/2026
Oncology
News
Administration of Live MMR Vaccine Appears Safe in Selected Post-Transplant Patients With Multiple Myeloma
03/26/2026
Emily Estrada
Results from a retrospective study suggest that measles-mumps-rubella vaccination appears safe in post-transplantation patients with multiple myeloma receiving daratumumab maintenance.
Results from a retrospective study suggest that measles-mumps-rubella vaccination appears safe in post-transplantation patients with multiple myeloma receiving daratumumab maintenance.
Results from a retrospective...
03/26/2026
Oncology
News
Belantamab Mafodotin Plus Bortezomib and Dexamethasone Demonstrates Clinical Activity in Relapsed or Refractory Multiple Myeloma
03/25/2026
Stephanie Holland
Results from Arm B of the phase 1/2 DREAMM-6 study demonstrated that belantamab mafodotin in combination with bortezomib and dexamethasone produced durable clinical activity across multiple dosing schedules in heavily pretreated patients with...
Results from Arm B of the phase 1/2 DREAMM-6 study demonstrated that belantamab mafodotin in combination with bortezomib and dexamethasone produced durable clinical activity across multiple dosing schedules in heavily pretreated patients with...
Results from Arm B of the phase...
03/25/2026
Oncology

News

News
FDA Grants Accelerated Approval to Iberdomide Combination for Relapsed or Refractory Multiple Myeloma
08/13/2026
Stephanie Holland
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated...
08/13/2026
Oncology
News
Phase 3 MonumenTAL-6 Trial Demonstrates Significant Survival Benefit With Dual-Bispecific Immunotherapy in Relapsed or Refractory Multiple Myeloma
07/23/2026
Stephanie Holland
Results from the phase 3 MonumenTAL-6 trial demonstrated that teclistamab plus talquetamab significantly improved progression-free and overall survival compared with standard therapy in patients with relapsed or refractory multiple myeloma,...
Results from the phase 3 MonumenTAL-6 trial demonstrated that teclistamab plus talquetamab significantly improved progression-free and overall survival compared with standard therapy in patients with relapsed or refractory multiple myeloma,...
Results from the phase 3...
07/23/2026
Oncology
News
Indefinite Lenalidomide Maintenance Fails to Improve Overall Survival in Standard-Risk Multiple Myeloma
07/16/2026
Stephanie Holland
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3...
07/16/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Mezigdomide Combination in Relapsed or Refractory Multiple Myeloma
07/13/2026
Stephanie Holland
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug...
07/13/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Significantly Improves Outcomes in Heavily Pretreated Relapsed or Refractory Multiple Myeloma
06/16/2026
Emily Estrada
Results from the SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma.
Results from the SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma.
Results from the SUCCESSOR-2...
06/16/2026
Oncology
News
Talquetamab-Based Regimens Improve Survival in Relapsed or Refractory Multiple Myeloma
06/16/2026
Stephanie Holland
Results from the phase 3 MonumenTAL-3 trial demonstrated that talquetamab-based regimens significantly improved outcomes compared with daratumumab plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma.
Results from the phase 3 MonumenTAL-3 trial demonstrated that talquetamab-based regimens significantly improved outcomes compared with daratumumab plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma.
Results from the phase 3...
06/16/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone in Heavily Pretreated Patients With R/R Multiple Myeloma
05/29/2026
Stephanie Holland
Results from the phase 3 SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in previously treated R/R multiple myeloma.
Results from the phase 3 SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in previously treated R/R multiple myeloma.
Results from the phase 3...
05/29/2026
Oncology
News
Maintenance Carfilzomib Plus Lenalidomide and Dexamethasone Following Autologous HSCT for Newly Diagnosed Multiple Myeloma
04/10/2026
Stephanie Holland
Results from the phase 3 ATLAS trial demonstrate that carfilzomib plus lenalidomide and dexamethasone significantly improves PFS in newly diagnosed patients with multiple myeloma following autologous hematopoietic stem-cell transplantation.
Results from the phase 3 ATLAS trial demonstrate that carfilzomib plus lenalidomide and dexamethasone significantly improves PFS in newly diagnosed patients with multiple myeloma following autologous hematopoietic stem-cell transplantation.
Results from the phase 3 ATLAS...
04/10/2026
Oncology
News
Administration of Live MMR Vaccine Appears Safe in Selected Post-Transplant Patients With Multiple Myeloma
03/26/2026
Emily Estrada
Results from a retrospective study suggest that measles-mumps-rubella vaccination appears safe in post-transplantation patients with multiple myeloma receiving daratumumab maintenance.
Results from a retrospective study suggest that measles-mumps-rubella vaccination appears safe in post-transplantation patients with multiple myeloma receiving daratumumab maintenance.
Results from a retrospective...
03/26/2026
Oncology
News
Belantamab Mafodotin Plus Bortezomib and Dexamethasone Demonstrates Clinical Activity in Relapsed or Refractory Multiple Myeloma
03/25/2026
Stephanie Holland
Results from Arm B of the phase 1/2 DREAMM-6 study demonstrated that belantamab mafodotin in combination with bortezomib and dexamethasone produced durable clinical activity across multiple dosing schedules in heavily pretreated patients with...
Results from Arm B of the phase 1/2 DREAMM-6 study demonstrated that belantamab mafodotin in combination with bortezomib and dexamethasone produced durable clinical activity across multiple dosing schedules in heavily pretreated patients with...
Results from Arm B of the phase...
03/25/2026
Oncology

Interactive Features

FDA Alerts
FDA Accepts New Drug Application for Mezigdomide Combination in Relapsed or Refractory Multiple Myeloma
07/13/2026
Stephanie Holland
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug...
07/13/2026
Oncology
Quiz
Oral Iberdomide Combination for R/R MM
02/24/2026
Test your knowledge on the safety profile of oral iberdomide plus low-dose cyclophosphamide and dexamethasone for patents with R/R multiple myeloma.
Test your knowledge on the safety profile of oral iberdomide plus low-dose cyclophosphamide and dexamethasone for patents with R/R multiple myeloma.
Test your knowledge on the...
02/24/2026
Oncology
Quiz
Daratumumab for High-Risk Smoldering Multiple Myeloma
10/30/2025
Emily Estrada
True or False: According to results from the phase 3 AQUILA study, fixed-duration subcutaneous daratumumab significantly prolonged PFS and delayed treatment initiation compared with active monitoring for patients with high-risk smoldering MM.
True or False: According to results from the phase 3 AQUILA study, fixed-duration subcutaneous daratumumab significantly prolonged PFS and delayed treatment initiation compared with active monitoring for patients with high-risk smoldering MM.
True or False: According to...
10/30/2025
Oncology
Quiz
Clarithromycin-Based Quadruplet Therapy for R/R MM
10/24/2025
True or False: For patients with R/R multiple myeloma, including those with high-risk cytogenetics, an all-oral combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated high response rates and prolonged...
True or False: For patients with R/R multiple myeloma, including those with high-risk cytogenetics, an all-oral combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated high response rates and prolonged...
True or False: For patients with...
10/24/2025
Oncology
Quiz
Pomalidomide-Based Regimen for Multiple Myeloma Treatment
09/19/2025
True or False: For patients with first-relapsed multiple myeloma, the addition of pomalidomide to bortezomib and dexamethasone demonstrated a significantly worse progression-free survival and overall response rate compared with control...
True or False: For patients with first-relapsed multiple myeloma, the addition of pomalidomide to bortezomib and dexamethasone demonstrated a significantly worse progression-free survival and overall response rate compared with control...
True or False: For patients with...
09/19/2025
Oncology
Quiz
Venetoclax Plus Bortezomib and Dexamethasone Therapy for R/R MM
08/04/2025
In the phase 3 BELLINI clinical trial, patients with R/R multiple myeloma who received venetoclax combined with bortezomib and dexamethasone demonstrated what median PFS compared to treatment with a placebo?
In the phase 3 BELLINI clinical trial, patients with R/R multiple myeloma who received venetoclax combined with bortezomib and dexamethasone demonstrated what median PFS compared to treatment with a placebo?
In the phase 3 BELLINI clinical...
08/04/2025
Oncology
Quiz
Belantamab Mafodotin Combination for R/R Multiple Myeloma
07/17/2025
In the DREAMM-8 trial, patients with multiple myeloma treated with belantamab mafodotin, pomalidomide, and dexamethasone demonstrated what median PFS compared to those receiving pomalidomide, bortezomib, and dexamethasone?
In the DREAMM-8 trial, patients with multiple myeloma treated with belantamab mafodotin, pomalidomide, and dexamethasone demonstrated what median PFS compared to those receiving pomalidomide, bortezomib, and dexamethasone?
In the DREAMM-8 trial, patients...
07/17/2025
Oncology
Quiz
Triplet Regimen for Relapsed/Refractory Multiple Myeloma
06/16/2025
What was the most common grade ≥ 3 adverse event associated with a weekly triplet regimen of carfilzomib, cyclophosphamide, and dexamethasone for patients with relapsed/refractory multiple myeloma?
What was the most common grade ≥ 3 adverse event associated with a weekly triplet regimen of carfilzomib, cyclophosphamide, and dexamethasone for patients with relapsed/refractory multiple myeloma?
What was the most common grade ≥...
06/16/2025
Oncology
Quiz
Anti-GPRC5D CAR T-Cell Therapy for Relapsed/Refractory MM
05/01/2025
According to a systematic review and meta-analysis, what proportion of patients with MM treated with anti-GPRC5D CAR T-cell therapy achieved complete response?
According to a systematic review and meta-analysis, what proportion of patients with MM treated with anti-GPRC5D CAR T-cell therapy achieved complete response?
According to a systematic review...
05/01/2025
Oncology
Quiz
GPRC5D-Targeted CAR T-Cell Therapy for Multiple Myeloma
04/02/2025
What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?
What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?
What was the reported...
04/02/2025
Oncology

Recent News

News
FDA Grants Accelerated Approval to Iberdomide Combination for Relapsed or Refractory Multiple Myeloma
08/13/2026
Stephanie Holland
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated...
08/13/2026
Oncology
News
Phase 3 MonumenTAL-6 Trial Demonstrates Significant Survival Benefit With Dual-Bispecific Immunotherapy in Relapsed or Refractory Multiple Myeloma
07/23/2026
Stephanie Holland
Results from the phase 3 MonumenTAL-6 trial demonstrated that teclistamab plus talquetamab significantly improved progression-free and overall survival compared with standard therapy in patients with relapsed or refractory multiple myeloma,...
Results from the phase 3 MonumenTAL-6 trial demonstrated that teclistamab plus talquetamab significantly improved progression-free and overall survival compared with standard therapy in patients with relapsed or refractory multiple myeloma,...
Results from the phase 3...
07/23/2026
Oncology
News
Indefinite Lenalidomide Maintenance Fails to Improve Overall Survival in Standard-Risk Multiple Myeloma
07/16/2026
Stephanie Holland
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3...
07/16/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Mezigdomide Combination in Relapsed or Refractory Multiple Myeloma
07/13/2026
Stephanie Holland
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug...
07/13/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Significantly Improves Outcomes in Heavily Pretreated Relapsed or Refractory Multiple Myeloma
06/16/2026
Emily Estrada
Results from the SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma.
Results from the SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma.
Results from the SUCCESSOR-2...
06/16/2026
Oncology
News
Talquetamab-Based Regimens Improve Survival in Relapsed or Refractory Multiple Myeloma
06/16/2026
Stephanie Holland
Results from the phase 3 MonumenTAL-3 trial demonstrated that talquetamab-based regimens significantly improved outcomes compared with daratumumab plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma.
Results from the phase 3 MonumenTAL-3 trial demonstrated that talquetamab-based regimens significantly improved outcomes compared with daratumumab plus pomalidomide and dexamethasone in relapsed or refractory multiple myeloma.
Results from the phase 3...
06/16/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone in Heavily Pretreated Patients With R/R Multiple Myeloma
05/29/2026
Stephanie Holland
Results from the phase 3 SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in previously treated R/R multiple myeloma.
Results from the phase 3 SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in previously treated R/R multiple myeloma.
Results from the phase 3...
05/29/2026
Oncology
News
Maintenance Carfilzomib Plus Lenalidomide and Dexamethasone Following Autologous HSCT for Newly Diagnosed Multiple Myeloma
04/10/2026
Stephanie Holland
Results from the phase 3 ATLAS trial demonstrate that carfilzomib plus lenalidomide and dexamethasone significantly improves PFS in newly diagnosed patients with multiple myeloma following autologous hematopoietic stem-cell transplantation.
Results from the phase 3 ATLAS trial demonstrate that carfilzomib plus lenalidomide and dexamethasone significantly improves PFS in newly diagnosed patients with multiple myeloma following autologous hematopoietic stem-cell transplantation.
Results from the phase 3 ATLAS...
04/10/2026
Oncology
News
Belantamab Mafodotin Plus Bortezomib and Dexamethasone Demonstrates Clinical Activity in Relapsed or Refractory Multiple Myeloma
03/25/2026
Stephanie Holland
Results from Arm B of the phase 1/2 DREAMM-6 study demonstrated that belantamab mafodotin in combination with bortezomib and dexamethasone produced durable clinical activity across multiple dosing schedules in heavily pretreated patients with...
Results from Arm B of the phase 1/2 DREAMM-6 study demonstrated that belantamab mafodotin in combination with bortezomib and dexamethasone produced durable clinical activity across multiple dosing schedules in heavily pretreated patients with...
Results from Arm B of the phase...
03/25/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Significantly Improves Progression-Free Survival in Relapsed or Refractory Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial showed that adding mezigdomide, an oral cereblon E3 ligase modulator, to carfilzomib and dexamethasone significantly improved progression-free survival compared with carfilzomib and...
Interim results from the phase 3 SUCCESSOR-2 trial showed that adding mezigdomide, an oral cereblon E3 ligase modulator, to carfilzomib and dexamethasone significantly improved progression-free survival compared with carfilzomib and...
Interim results from the phase 3...
03/11/2026
Oncology
News
FDA Grants Accelerated Approval to Iberdomide Combination for Relapsed or Refractory Multiple Myeloma
08/13/2026
Stephanie Holland
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated...
08/13/2026
Oncology
News
Perioperative Enfortumab Vedotin Plus Pembrolizumab Outperforms Cisplatin Plus Gemcitabine in Muscle-Invasive Bladder Cancer
08/12/2026
Stephanie Holland
Results from the phase 3 KEYNOTE-B15/EV-304 trial showed that perioperative enfortumab vedotin plus pembrolizumab improved survival and response compared with neoadjuvant cisplatin plus gemcitabine in cisplatin-eligible muscle-invasive...
Results from the phase 3 KEYNOTE-B15/EV-304 trial showed that perioperative enfortumab vedotin plus pembrolizumab improved survival and response compared with neoadjuvant cisplatin plus gemcitabine in cisplatin-eligible muscle-invasive...
Results from the phase 3...
08/12/2026
Oncology
News
BEGONIA Shows No Added Benefit With Capivasertib or Oleclumab Added to Durvalumab Plus Paclitaxel in Advanced Triple-Negative Breast Cancer
08/12/2026
Emily Estrada
Results from the phase 1b/2 BEGONIA trial showed clinical activity with first-line durvalumab plus paclitaxel in unresectable locally advanced or metastatic triple-negative breast cancer, while adding capivasertib or oleclumab provided no...
Results from the phase 1b/2 BEGONIA trial showed clinical activity with first-line durvalumab plus paclitaxel in unresectable locally advanced or metastatic triple-negative breast cancer, while adding capivasertib or oleclumab provided no...
Results from the phase 1b/2...
08/12/2026
Oncology
News
Subcutaneous Pertuzumab Plus Trastuzumab Shows Comparable 4-Year Outcomes to Intravenous Therapy in HER2-Positive Breast Cancer
08/12/2026
Emily Estrada
Long-term results from the phase 3 FeDeriCa trial showed that fixed-dose subcutaneous pertuzumab plus trastuzumab maintained efficacy and a comparable safety profile versus intravenous therapy in HER2-positive early breast cancer, supporting...
Long-term results from the phase 3 FeDeriCa trial showed that fixed-dose subcutaneous pertuzumab plus trastuzumab maintained efficacy and a comparable safety profile versus intravenous therapy in HER2-positive early breast cancer, supporting...
Long-term results from the phase...
08/12/2026
Oncology
News
Foundation AI Model Surpasses Early-Career Dermatologists but Falls Short of Experts in Skin Cancer Diagnosis
08/12/2026
Stephanie Holland
A multicenter diagnostic study found that a modern artificial intelligence (AI) foundation model outperformed physicians with fewer than 3 years of dermatology experience and matched midcareer clinicians in skin cancer diagnosis but remained...
A multicenter diagnostic study found that a modern artificial intelligence (AI) foundation model outperformed physicians with fewer than 3 years of dermatology experience and matched midcareer clinicians in skin cancer diagnosis but remained...
A multicenter diagnostic study...
08/12/2026
Oncology
News
Two Injection Sites Outperformed Single-Site Delivery for Melanoma Peptide Vaccine
08/12/2026
Stephanie Holland
Long-term results from a randomized phase 2 trial showed that administering a 12-peptide melanoma vaccine at 2 injection sites significantly improved recurrence-free survival in patients with resected high-risk melanoma, whereas adding GM-CSF...
Long-term results from a randomized phase 2 trial showed that administering a 12-peptide melanoma vaccine at 2 injection sites significantly improved recurrence-free survival in patients with resected high-risk melanoma, whereas adding GM-CSF...
Long-term results from a...
08/12/2026
Oncology
News
Sonrotoclax Monotherapy Demonstrates Meaningful Activity in Heavily Pretreated Mantle Cell Lymphoma
08/12/2026
Emily Estrada
Results from a phase 1/2 study showed that sonrotoclax monotherapy produced rapid and durable responses with a manageable safety profile in patients with relapsed or refractory mantle cell lymphoma previously treated with anti-CD20–based...
Results from a phase 1/2 study showed that sonrotoclax monotherapy produced rapid and durable responses with a manageable safety profile in patients with relapsed or refractory mantle cell lymphoma previously treated with anti-CD20–based...
Results from a phase 1/2 study...
08/12/2026
Oncology
News
Ociperlimab Plus Tislelizumab Fails to Improve Survival Over Pembrolizumab in PD-L1-High Advanced Non-Small Cell Lung Cancer
08/11/2026
Emily Estrada
Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...
Ociperlimab plus tislelizumab failed to improve overall survival compared with pembrolizumab as first-line treatment for patients with stage III/IV non-small cell lung cancer and PD-L1 expression of ≥50%, leading to the phase 3 AdvanTIG-302...
Ociperlimab plus tislelizumab...
08/11/2026
Oncology
News
IO102-IO103 Plus Nivolumab and Relatlimab Demonstrates Encouraging Activity in Unresectable Melanoma
08/05/2026
Stephanie Holland
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated that the investigational cancer vaccine IO102-IO103 combined with nivolumab and relatlimab achieved a 60% objective response rate in previously untreated unresectable melanoma, supporting further evaluation of the...
A phase 2 trial demonstrated...
08/05/2026
Oncology
News
HBI-8000 Plus Nivolumab Significantly Improves Progression-Free Survival in Advanced Melanoma
08/05/2026
Stephanie Holland
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global phase 3 trial demonstrated that HBI-8000 plus nivolumab significantly improved progression-free survival compared with nivolumab alone in patients with advanced melanoma, supporting the combination as a potential...
Topline results from a global...
08/05/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use